March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Lipoxin A4 (lxa4) Decreases Platelet-activating Factor (PAF) Inflammatory Response And In Turn Stimulates Corneal Wound Healing
Author Affiliations & Notes
  • Azucena H. Kakazu
    Ophthalmology/Neuroscience Center, LSU Health Sciences Center, New Orleans, Louisiana
  • Jiucheng He
    Ophthalmology/Neuroscience Center, LSU Health Sciences Center, New Orleans, Louisiana
  • Tiffany C. Russ
    Ophthalmology/Neuroscience Center, LSU Health Sciences Center, New Orleans, Louisiana
  • Haydee E. Bazan
    Ophthalmology/Neuroscience Center, LSU Health Sciences Center, New Orleans, Louisiana
  • Footnotes
    Commercial Relationships  Azucena H. Kakazu, None; Jiucheng He, None; Tiffany C. Russ, None; Haydee E. Bazan, None
  • Footnotes
    Support  NIH Grant EY04928
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3575. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Azucena H. Kakazu, Jiucheng He, Tiffany C. Russ, Haydee E. Bazan; Lipoxin A4 (lxa4) Decreases Platelet-activating Factor (PAF) Inflammatory Response And In Turn Stimulates Corneal Wound Healing. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3575.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Platelet-activating factor (PAF) is a strong bioactive inflammatory mediator that inhibits corneal wound healing. The action of PAF is blocked by the novel PAF receptor antagonist LAU-0901 (ARVO 2011). Lipoxin A4 (LXA4), a lipid mediator derived from arachidonic acid by the action of a 15-lipoxigenase, is involved in inflammation resolution and tissue repair. The purpose of this study was to evaluate the action of LXA4 on an in vivo mouse model of corneal epithelial and stromal injury sustained by PAF.

Methods: : Male 5-7-week-old C57BL/6 mice were used. The corneal epithelium and anterior stroma (about 25%) from one eye was removed up to the limbal border using an Algerbrush II with a 0.5 mm burr under a surgical microscope. The mice were treated topically with 10µg/ml PAF (5µl) once a day, LXA4 (1µg) 3 times/day or both together. Mice were euthanized at 1, 2, and 7 days after injury, and corneas were excised and processed for histopathology (H&E staining). ELISA, enzymatic activity for myeloperoxidase (MPO) , or immunofluorescence staining with antibodies for metalloproteinase-9 (MMP-9), interlukin-1α ( IL-1α), keratinocyte-derived chemokine (KC/CXCL1), α-smooth muscle actin (α-SMA), neutrophils and MPO were performed.

Results: : Topical treatment with LXA4 suppressed the effect of PAF on wound healing. At day 1, the injury area was reduced up to 80% compared to PAF alone, and at day 2 by up to 95%. By day 7, the healing was complete. The strong stromal cell infiltration and neutrophil recruitment induced by PAF was decrease with LXA4 treatment. The activity and expression of MPO were also decreased. LXA4 blocked PAF- induced MMP-9 and cytokines IL-1α and KC expression.

Conclusions: : PAF is a strong inflammatory mediator and a potent activator of MMP-9 that delays cornea wound healing. The potent counteracting action of LXA4 in arresting the sustained inflammatory response of PAF suggests the potential use of this lipoxin as a therapeutic tool in treating corneal injuries that compromise the stroma.

Keywords: wound healing • inflammation • lipids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×